This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content
MONTREAL, Sept. 01, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has received regulatory approval from INVIMA, the Colombian health regulatory agency, for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intravenous immunoglobulin.1
Sign In or Create an Account
or View more offersArticle content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
“We are pleased to receive regulatory approval of TAVALISSE in Colombia, providing an important new therapeutic option for adult patients living with chronic immune thrombocytopenia,” said Samira Sakhia, President and CEO of Knight Therapeutics. “This approval represents a meaningful step in addressing unmet medical needs in Colombia and underscores our ongoing commitment to expanding access to innovative treatments and improving patient outcomes across Latin America. We look forward to bringing TAVALISSE to patients and healthcare providers in Colombia in the near future.”
Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article contentArticle content
Knight announced its agreement with Rigel Pharmaceuticals, Inc. in May 2022, securing exclusive rights to commercialize TAVALISSE in Latin America. Since entering the agreement, Knight has made significant regulatory progress throughout the region and has submitted TAVALISSE for regulatory approval in Brazil, Colombia, Mexico, Argentina and Paraguay. Knight launched TAVALISSE in Mexico in May 2026 and expects to launch in Brazil in the fourth quarter of 2026 and in Colombia in the first half of 2027.
Article content
Story continues below
This advertisement has not loaded yet, but your article continues below.
Article content
About TAVALISSE®
Article content
TAVALISSE® (fostamatinib disodium hexahydrate) is an orally administered spleen tyrosine kinase (SYK) inhibitor. It is currently marketed in the United States under the brand name TAVALISSE (100mg and 150mg tablets) and in Europe under the brand name TAVLESSE for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.2
Article content
TAVALISSE® is a registered trademark of Rigel Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.
Article content
About Chronic Immune Thrombocytopenia (ITP)
Article content
In patients with ITP, the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding.3 People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death.4
Article content
About Knight Therapeutics Inc.
Article content
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.